Neutralizing anti-drug antibodies in Fabry disease have no obvious clinical impact?

被引：3

作者：

Lenders, Malte ^{[1
]}

Schmitz, Boris ^{[2
]}

Brand, Stefan-Martin ^{[2
]}

Brand, Eva ^{[1
]}

机构：

[1] Univ Hosp Muenster, Dept Nephrol Hypertens & Rheumatol, Internal Med D, Albert Schweitzer Campus 1, D-48149 Munster, Germany

[2] Univ Hosp Muenster, Inst Sports Med, Mol Genet Cardiovasc Dis, Munster, Germany

来源：

ORPHANET JOURNAL OF RARE DISEASES | 2018年 / 13卷

关键词：

Enzyme replacement therapy; Longitudinal; Prospective; REPLACEMENT THERAPY; MEMBRANOUS NEPHROPATHY; AGALSIDASE-ALPHA; BETA;

D O I：

10.1186/s13023-018-0916-1

中图分类号：

Q3 [遗传学];

学科分类号：

071007 ; 090102 ;

摘要：

Fabry disease (FD) is a rare X-linked disorder caused by a deficiency of lysosomal a-galactosidase A activity. Treatment with recombinant enzyme replacement therapy is available since 2001 and the effects of anti-drug antibodies (ADA) on therapy efficacy and disease outcome in affected patients have been controversially reported. In this letter we discuss the importance of adequate measurements of neutralizing ADAs and appropriate longitudinal analysis to determine therapy efficiency and clinical outcome in patients with FD.

引用

页数：2

共 50 条

[21] Alemtuzumab depletion failure and neutralizing anti-drug antibodies: a case report and call for monitoring
Munger, K.
Kang, A.
Baker, D.
Goodman, A.
Samkoff, L.
MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 258 - 258
[22] Clinically important neutralizing anti-drug antibodies detected with an in-house competitive ELISA
Manca Ogrič
Polona Žigon
Katja Lakota
Sonja Praprotnik
David Drobne
Borut Štabuc
Snezna Sodin-Semrl
Saša Čučnik
Clinical Rheumatology, 2019, 38 : 361 - 370
[23] ANTI-DRUG ANTIBODIES TO INFLIXIMAB: A COMPARISON OF FREE ANTI-DRUG ANTIBODY MEASUREMENT
Hamilton, Rhona
Shields, Stephanie
Macdonald, Jonathan
Dunlop, Allan
Perry, Martin
McGucken, Andrew
Gribben, Elain
Galloway, Peter
GUT, 2021, 70 : A121 - A121
[24] Alemtuzumab Depletion Failure and Neutralizing Anti-Drug Antibodies: a Case Report and Call for Monitoring
Munger, Kathleen
Kang, Angray
Baker, David
Goodman, Andrew
Samkoff, Lawrence
NEUROLOGY, 2020, 94 (15)
[25] Anti-drug Antibodies Monitoring in Biologics Use: Clinical Implications
Dhahri, Rim
Athimni, Selma
Slouma, Maroua
Metoui, Leila
Gharsallah, Imene
Louzir, Bassem
CURRENT REVIEWS IN CLINICAL AND EXPERIMENTAL PHARMACOLOGY, 2021, 16 (03) : 235 - 238
[26] Anti-TNF levels and anti-drug antibodies, immunosuppressants and clinical outcomes in inflammatory bowel disease
Ha, Christina
Mathur, Jagrati
Kornbluth, Asher
EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2015, 9 (04) : 497 - 505
[27] Prevalence of anti-drug antibodies against interferon beta has decreased since routine analysis of neutralizing antibodies became clinical practice
Jungedal, Roger
Lundkvist, Malin
Engdahl, Elin
Ramanujam, Ryan
Westerlind, Helga
Sominanda, Ajith
Hillert, Jan
Fogdell-Hahn, Anna
MULTIPLE SCLEROSIS JOURNAL, 2012, 18 (12) : 1775 - 1781
[28] Anti-Drug Antibodies Detected in the Presence of Adequate Infliximab Drug Levels In IBD Patients in Clinical Remission have Limited Clinical Significance
Doherty, J.
Varley, R.
Healy, M.
Dunne, C.
Mac Carthy, F.
McKiernan, S.
Hartery, K.
Kevans, D.
JOURNAL OF CROHNS & COLITIS, 2021, 15 : S415 - S416
[29] ANTI-DRUG ANTIBODIES DETECTED IN THE PRESENCE OF ADEQUATE INFLIXIMAB DRUG LEVELS IN IBD PATIENTS IN CLINICAL REMISSION HAVE LIMITED CLINICAL SIGNIFICANCE
Doherty, Jayne
Varley, Rachel
Healy, Martin
Dunne, Cara
Maccarthy, Finbar
Mckiernan, Susan
Hartery, Karen
Kevans, David
GASTROENTEROLOGY, 2021, 160 (06) : S692 - S692
[30] Methotrexate BAFFles anti-drug antibodies
Cronstein, Bruce N.
NATURE REVIEWS RHEUMATOLOGY, 2018, 14 (09) : 505 - 506

← 1 2 3 4 5 →